## Eric S White

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9125451/publications.pdf

Version: 2024-02-01

161 15,284 67
papers citations h-index

7 119
adex g-index

166 166 all docs citations

166 times ranked 17784 citing authors

#	Article	IF	CITATIONS
1	Repair and Regeneration of the Respiratory System: Complexity, Plasticity, and Mechanisms of Lung Stem Cell Function. Cell Stem Cell, 2014, 15, 123-138.	11.1	748
2	Mechanisms of Pulmonary Fibrosis. Annual Review of Medicine, 2004, 55, 395-417.	12.2	640
3	In vitro generation of human pluripotent stem cell derived lung organoids. ELife, 2015, 4, .	6.0	605
4	The myofibroblast matrix: implications for tissue repair andÂfibrosis. Journal of Pathology, 2013, 229, 298-309.	4.5	560
5	Acellular Normal and Fibrotic Human Lung Matrices as a Culture System for <i>In Vitro</i> Investigation. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 866-876.	5.6	552
6	Myofibroblast Differentiation by Transforming Growth Factor-ॆ1 Is Dependent on Cell Adhesion and Integrin Signaling via Focal Adhesion Kinase. Journal of Biological Chemistry, 2003, 278, 12384-12389.	3.4	547
7	Fibrotic extracellular matrix activates a profibrotic positive feedback loop. Journal of Clinical Investigation, 2014, 124, 1622-1635.	8.2	444
8	Targeted Injury of Type II Alveolar Epithelial Cells Induces Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 254-263.	5.6	399
9	Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respiratory Medicine, the, 2014, 2, 548-556.	10.7	353
10	The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease. European Respiratory Journal, 2017, 50, 1601805.	6.7	341
11	An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 667-679.	2.9	267
12	An Essential Role for Fibronectin Extra Type III Domain A in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 638-645.	5.6	257
13	Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2012, 303, L1046-L1056.	2.9	223
14	Combinatorial activation of FAK and AKT by transforming growth factor $\hat{J}^21$ confers an anoikis-resistant phenotype to myofibroblasts. Cellular Signalling, 2007, 19, 761-771.	3.6	220
15	Human iPS cellââ,¬â€œderived alveolar epithelium repopulates lung extracellular matrix. Journal of Clinical Investigation, 2013, 123, 4950-4962.	8.2	214
16	Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1127-1138.	<b>5.</b> 6	205
17	Extracellular matrix in lung development, homeostasis and disease. Matrix Biology, 2018, 73, 77-104.	3.6	200
18	Future Directions in Idiopathic Pulmonary Fibrosis Research. An NHLBI Workshop Report. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 214-222.	5.6	199

#	Article	IF	CITATIONS
19	Fibronectin <sup>EDA</sup> Promotes Chronic Cutaneous Fibrosis Through Toll-Like Receptor Signaling. Science Translational Medicine, 2014, 6, 232ra50.	12.4	195
20	InÂVitro Induction and InÂVivo Engraftment of Lung Bud Tip Progenitor Cells Derived from Human Pluripotent Stem Cells. Stem Cell Reports, 2018, 10, 101-119.	4.8	192
21	Joint SNMMI–ASNC Expert Consensus Document on the Role of <sup>18</sup> F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring. Journal of Nuclear Medicine, 2017, 58, 1341-1353.	5.0	187
22	Negative Regulation of Myofibroblast Differentiation by PTEN (Phosphatase and Tensin Homolog) Tj ETQq0 0 0 rg	gBT /Overl 5.6	ock 10 Tf 50 186
23	Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis. Journal of Pathology, 2003, 201, 343-354.	4.5	166
24	Chitinase 3–Like 1 Suppresses Injury and Promotes Fibroproliferative Responses in Mammalian Lung Fibrosis. Science Translational Medicine, 2014, 6, 240ra76.	12.4	162
25	A bioengineered niche promotes in vivo engraftment and maturation of pluripotent stem cell derived human lung organoids. ELife, 2016, 5, .	6.0	162
26	Generation of tissue-engineered small intestine using embryonic stem cell-derived human intestinal organoids. Biology Open, 2015, 4, 1462-1472.	1.2	151
27	Blue Journal Conference. Aging and Susceptibility to Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 261-269.	5.6	149
28	Hypersensitivity Pneumonitis. Chest, 2019, 155, 699-711.	0.8	148
29	Lung Extracellular Matrix and Fibroblast Function. Annals of the American Thoracic Society, 2015, 12, S30-S33.	3.2	145
30	Fibronectin splice variants: Understanding their multiple roles in health and disease using engineered mouse models. IUBMB Life, 2011, 63, 538-546.	3.4	141
31	Extensive Phenotyping of Individuals at Risk for Familial Interstitial Pneumonia Reveals Clues to the Pathogenesis of Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 417-426.	5.6	141
32	Inhibition of Myocardin-Related Transcription Factor/Serum Response Factor Signaling Decreases Lung Fibrosis and Promotes Mesenchymal Cell Apoptosis. American Journal of Pathology, 2015, 185, 969-986.	3.8	138
33	The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. Journal of Clinical Investigation, 2010, 120, 1950-1960.	8.2	138
34	Prostaglandin E <sub>2</sub> induces fibroblast apoptosis by modulating multiple survival pathways. FASEB Journal, 2009, 23, 4317-4326.	0.5	132
35	Joint SNMMI–ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. Journal of Nuclear Cardiology, 2017, 24, 1741-1758.	2.1	132
36	Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1242-1251.	5.6	131

#	Article	IF	CITATIONS
37	EDAâ€containing cellular fibronectin induces fibroblast differentiation through binding to α <sub>4</sub> l² <sub>7</sub> integrin receptor and MAPK/Erk 1/2â€dependent signaling. FASEB Journal, 2010, 24, 4503-4512.	0.5	130
38	Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 208-219.	5.6	130
39	Integrin $\hat{l}_{\pm}$ <sub>4</sub> $\hat{l}^{2}$ <sub>1</sub> Regulates Migration across Basement Membranes by Lung Fibroblasts. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 436-442.	5.6	128
40	Hypermethylation of PTGER2 Confers Prostaglandin E2 Resistance in Fibrotic Fibroblasts from Humans and Mice. American Journal of Pathology, 2010, 177, 2245-2255.	3.8	127
41	Prostaglandin E2Inhibits Fibroblast Migration by E-Prostanoid 2 Receptor–Mediated Increase in PTEN Activity. American Journal of Respiratory Cell and Molecular Biology, 2005, 32, 135-141.	2.9	124
42	Bleomycin-Induced E Prostanoid Receptor Changes Alter Fibroblast Responses to Prostaglandin E2. Journal of Immunology, 2005, 174, 5644-5649.	0.8	123
43	Histone modifications are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblasts. Cell Death and Disease, 2013, 4, e621-e621.	6.3	122
44	The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood, 2008, 112, 3073-3081.	1.4	117
45	Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clinical Cancer Research, 2003, 9, 853-60.	7.0	117
46	Lysyl oxidases regulate fibrillar collagen remodelling in idiopathic pulmonary fibrosis. DMM Disease Models and Mechanisms, 2017, 10, 1301-1312.	2.4	110
47	The ED-A domain enhances the capacity of fibronectin to store latent TGF- $\hat{l}^2$ binding protein-1 in the fibroblast matrix. Journal of Cell Science, 2018, 131, .	2.0	107
48	Optimising experimental research in respiratory diseases: an ERS statement. European Respiratory Journal, 2018, 51, 1702133.	6.7	98
49	miR-92a regulates TGF-β1-induced WISP1 expression in pulmonary fibrosis. International Journal of Biochemistry and Cell Biology, 2014, 53, 432-441.	2.8	95
50	Leptin Modulates Neutrophil Phagocytosis of Klebsiella pneumoniae. Infection and Immunity, 2003, 71, 4182-4185.	2.2	93
51	Inflammation, wound repair, and fibrosis: reassessing the spectrum of tissue injury and resolution. Journal of Pathology, 2013, 229, 141-144.	4.5	91
52	Matrix Biology of Idiopathic Pulmonary Fibrosis. American Journal of Pathology, 2014, 184, 1643-1651.	3.8	91
53	Non-Small Cell Lung Cancer Cells Induce Monocytes to Increase Expression of Angiogenic Activity. Journal of Immunology, 2001, 166, 7549-7555.	0.8	90
54	PGE2 inhibition of TGF-Î <sup>2</sup> 1-induced myofibroblast differentiation is Smad-independent but involves cell shape and adhesion-dependent signaling. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 293, L417-L428.	2.9	90

#	Article	IF	CITATIONS
55	FOXM1 is a critical driver of lung fibroblast activation and fibrogenesis. Journal of Clinical Investigation, 2018, 128, 2389-2405.	8.2	88
56	Pulmonary Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 053-074.	2.1	87
57	Utility of Transbronchial vsÂSurgical Lung Biopsy in the Diagnosis of Suspected Fibrotic Interstitial Lung Disease. Chest, 2017, 151, 389-399.	0.8	87
58	Coevolution of T <sub>H</sub> 1, T <sub>H</sub> 2, and T <sub>H</sub> 17 Responses during Repeated Pulmonary Exposure to <i>Aspergillus fumigatus</i> Conidia. Infection and Immunity, 2011, 79, 125-135.	2.2	86
59	MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis. ERJ Open Research, 2017, 3, 00074-2016.	2.6	86
60	Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respiratory Medicine, 2009, 103, 268-273.	2.9	85
61	Prostaglandin E2 Inhibits α-Smooth Muscle Actin Transcription during Myofibroblast Differentiation via Distinct Mechanisms of Modulation of Serum Response Factor and Myocardin-related Transcription Factor-A. Journal of Biological Chemistry, 2014, 289, 17151-17162.	3.4	84
62	The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. Lancet Respiratory Medicine, the, 2017, 5, 61-71.	10.7	79
63	Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome after Allogeneic Stem Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network Protocol. Biology of Blood and Marrow Transplantation. 2014. 20. 858-864.	2.0	78
64	Conformational coupling of integrin and Thy-1 regulates Fyn priming and fibroblast mechanotransduction. Journal of Cell Biology, 2015, 211, 173-190.	<b>5.</b> 2	78
65	$\hat{l}\pm\nu\hat{l}^2$ 3 Integrin drives fibroblast contraction and strain stiffening of soft provisional matrix during progressive fibrosis. JCI Insight, 2018, 3, .	5.0	78
66	Interleukin-17 Drives Pulmonary Eosinophilia following Repeated Exposure to Aspergillus fumigatus Conidia. Infection and Immunity, 2012, 80, 1424-1436.	2.2	76
67	Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis. International Journal of Biochemistry and Cell Biology, 2012, 44, 158-169.	2.8	73
68	Hsp90 regulation of fibroblast activation in pulmonary fibrosis. JCI Insight, 2017, 2, e91454.	5.0	73
69	Lung Fibroblasts from Patients with Idiopathic Pulmonary Fibrosis Exhibit Genome-Wide Differences in DNA Methylation Compared to Fibroblasts from Nonfibrotic Lung. PLoS ONE, 2014, 9, e107055.	2.5	70
70	Comparative biology of decellularized lung matrix: Implications of species mismatch in regenerative medicine. Biomaterials, 2016, 102, 220-230.	11.4	68
71	Senescent Cells Contribute to the Physiological Remodeling of Aged Lungs. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 153-160.	3.6	65
72	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respiratory Medicine, the, 2019, 7, 771-779.	10.7	65

#	Article	IF	Citations
73	Improved survival in tumor-bearing SCID mice treated with interferon- $\hat{I}^3$ -inducible protein 10 (IP-10/CXCL10). Cancer Immunology, Immunotherapy, 2001, 50, 533-538.	4.2	63
74	Plasminogen Activator Inhibitor–1 Impairs Alveolar Epithelial Repair by Binding to Vitronectin. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 672-678.	2.9	62
75	TNF-Receptor Inhibitor Therapy for the Treatment of Children with Idiopathic Pneumonia Syndrome. A Joint Pediatric Blood and Marrow Transplant Consortium and Children's Oncology Group Study (ASCT0521). Biology of Blood and Marrow Transplantation, 2015, 21, 67-73.	2.0	62
76	PTEN Directly Activates the Actin Depolymerization Factor Cofilin-1 During PGE <sub>2</sub> -Mediated Inhibition of Phagocytosis of Fungi. Science Signaling, 2012, 5, ra12.	3.6	61
77	Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts. Advances in Bioscience and Biotechnology (Print), 2012, 03, 657-664.	0.7	61
78	Dietary influences on morphine-induced analgesia in rats. Pharmacology Biochemistry and Behavior, 1991, 38, 681-684.	2.9	60
79	X-Linked Inhibitor of Apoptosis Regulates Lung Fibroblast Resistance to Fas-Mediated Apoptosis. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 86-95.	2.9	60
80	Control of fibroblast fibronectin expression and alternative splicing via the PI3K/Akt/mTOR pathway. Experimental Cell Research, 2010, 316, 2644-2653.	2.6	59
81	Development and validation of a radiological diagnosis model for hypersensitivity pneumonitis. European Respiratory Journal, 2018, 52, 1800443.	6.7	55
82	Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1339-1349.	5.6	54
83	Bronchiolar Complications of Connective Tissue Diseases. Seminars in Respiratory and Critical Care Medicine, 2003, 24, 543-566.	2.1	51
84	Netrinâ€1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycinâ€Induced Pulmonary Fibrosis. Arthritis and Rheumatology, 2016, 68, 1251-1261.	5.6	51
85	The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes. Scientific Reports, 2017, 7, 46560.	3.3	51
86	Recipientâ€derived EDA fibronectin promotes cardiac allograft fibrosis. Journal of Pathology, 2012, 226, 609-618.	4.5	50
87	Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for Subacute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1044-1054.	2.0	48
88	IL- $36\hat{l}^3$ is secreted in microparticles and exosomes by lung macrophages in response to bacteria and bacterial components. Journal of Leukocyte Biology, 2016, 100, 413-421.	3.3	47
89	Arsenic trioxide inhibits transforming growth factor- $\hat{l}^21$ -induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo. Respiratory Research, 2014, 15, 51.	3.6	46
90	Activation of Phosphatase and Tensin Homolog on Chromosome 10 Mediates the Inhibition of $Fcl^3R$ Phagocytosis by Prostaglandin E2 in Alveolar Macrophages. Journal of Immunology, 2007, 179, 8350-8356.	0.8	44

#	Article	IF	Citations
91	The tumor suppressor protein PTEN inhibits rat hepatic stellate cell activation. Journal of Gastroenterology, 2009, 44, 847-855.	5.1	44
92	Pharmacological Therapy for Wegener???s Granulomatosis. Drugs, 2006, 66, 1209-1228.	10.9	43
93	Six-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPF. PLoS ONE, 2016, 11, e0159878.	2.5	43
94	Usual Interstitial Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2006, 27, 634-651.	2.1	42
95	PTEN Regulates Fibroblast Elimination during Collagen Matrix Contraction. Journal of Biological Chemistry, 2006, 281, 33291-33301.	3.4	41
96	Downregulation of FAK-related non-kinase mediates the migratory phenotype of human fibrotic lung fibroblasts. Experimental Cell Research, 2010, 316, 1600-1609.	2.6	41
97	Corticosteroids in idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2001, 7, 298-308.	2.6	36
98	Discoidin Domain Receptor 2 Signaling Regulates Fibroblast Apoptosis through PDK1/Akt. American Journal of Respiratory Cell and Molecular Biology, 2018, 59, 295-305.	2.9	35
99	Bioengineered lungs generated from human i <scp>PSC</scp> sâ€derived epithelial cells on native extracellular matrix. Journal of Tissue Engineering and Regenerative Medicine, 2018, 12, e1623-e1635.	2.7	35
100	Usual Interstitial Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2001, 22, 357-386.	2.1	34
101	Monocyte-Fibronectin Interactions, Via $\hat{l}\pm 5\hat{l}^21$ Integrin, Induce Expression of CXC Chemokine-Dependent Angiogenic Activity. Journal of Immunology, 2001, 167, 5362-5366.	0.8	33
102	Diversity of the Angiogenic Phenotype in Non–Small Cell Lung Cancer. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 343-350.	2.9	32
103	Repeated Exposure to Aspergillus fumigatus Conidia Results in CD4 <sup>+</sup> T Cell-Dependent and -Independent Pulmonary Arterial Remodeling in a Mixed Th1/Th2/Th17 Microenvironment That Requires Interleukin-4 (IL-4) and IL-10. Infection and Immunity, 2012, 80, 388-397.	2.2	32
104	Wilms $\hat{a} \in \mathbb{N}$ tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease. JCI Insight, 2018, 3, .	5.0	32
105	Tissue Inhibitor of Matrix-Metalloprotease–1 Predicts Risk of Hepatic Fibrosis in Human Schistosoma japonicum Infection. Journal of Infectious Diseases, 2011, 203, 707-714.	4.0	31
106	Recommendations for minimum information for publication ofÂexperimental pathology data: <scp>MINPEPA</scp> guidelines. Journal of Pathology, 2016, 238, 359-367.	4.5	31
107	Frailty and geriatric conditions in older patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 148, 6-12.	2.9	31
108	Wegener's Granulomatosis: Evolving Concepts in Treatment. Seminars in Respiratory and Critical Care Medicine, 2004, 25, 491-521.	2.1	30

#	Article	IF	Citations
109	Up-Regulation of Heparan Sulfate 6-O-Sulfation in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2014, 50, 106-114.	2.9	30
110	Fibrocytes Regulate Wilms Tumor 1–Positive Cell Accumulation in Severe Fibrotic Lung Disease. Journal of Immunology, 2015, 195, 3978-3991.	0.8	29
111	Development and Initial Validation Analyses of the Living with Idiopathic Pulmonary Fibrosis Questionnaire. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1689-1697.	5 <b>.</b> 6	27
112	Detection and Early Referral of Patients With Interstitial Lung Abnormalities. Chest, 2022, 161, 470-482.	0.8	26
113	PTEN Limits Alveolar Macrophage Function against <i>Pseudomonas aeruginosa</i> Transplantation. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 1050-1058.	2.9	24
114	An American Thoracic Society Official Research Statement: Future Directions in Lung Fibrosis Research. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 792-800.	5.6	22
115	Current and emerging strategies for the management of sarcoidosis. Expert Opinion on Pharmacotherapy, 2007, 8, 1293-1311.	1.8	21
116	Phosphatase and Tensin Homologue on Chromosome 10 (PTEN) Directs Prostaglandin E2-mediated Fibroblast Responses via Regulation of E Prostanoid 2 Receptor Expression. Journal of Biological Chemistry, 2009, 284, 32264-32271.	3.4	20
117	Fibrotic and Sclerotic Manifestations of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2012, 18, S46-S52.	2.0	20
118	Understanding Chronic GVHD from Different Angles. Biology of Blood and Marrow Transplantation, 2012, 18, S184-S188.	2.0	20
119	Radiographic Honeycombing and Altered Lung Microbiota in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1544-1547.	5.6	20
120	Human antigen R promotes lung fibroblast differentiation to myofibroblasts and increases extracellular matrix production. Journal of Cellular Physiology, 2021, 236, 6836-6851.	4.1	17
121	Maternal Infection with Schistosoma japonicum Induces a Profibrotic Response in Neonates. Infection and Immunity, 2014, 82, 350-355.	2.2	16
122	Open-Access Biorepository for Idiopathic Pulmonary Fibrosis. The Way Forward. Annals of the American Thoracic Society, 2014, 11, 1171-1175.	3.2	15
123	Loss of CDKN2B Promotes Fibrosis via Increased Fibroblast Differentiation Rather Than Proliferation. American Journal of Respiratory Cell and Molecular Biology, 2018, 59, 200-214.	2.9	15
124	Sarcoidosis Involving Multiple Systems. Chest, 2001, 119, 1593-1597.	0.8	14
125	Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial. BMJ Open Respiratory Research, 2018, 5, e000325.	3.0	14
126	Increased circulating desmosine and age-dependent elastinolysis in idiopathic pulmonary fibrosis. Respiratory Research, 2018, 19, 45.	3.6	12

#	Article	IF	CITATIONS
127	Type I Collagen Signaling Regulates Opposing Fibrotic Pathways through $\hat{l}\pm\langle sub\rangle 2\langle sub\rangle \hat{l}^2\langle sub\rangle 1\langle sub\rangle$ Integrin. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 613-622.	2.9	12
128	Infliximab in Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 732-733.	5.6	11
129	Pneumocystis Pneumonia Increases the Susceptibility of Mice to Sublethal Hyperoxia. Infection and Immunity, 2003, 71, 5970-5978.	2.2	10
130	Identification of a unique temporal signature in blood and BAL associated with IPF progression. Scientific Reports, 2020, 10, 12049.	3.3	10
131	Animal and cellular models of human disease. Journal of Pathology, 2016, 238, 137-140.	4.5	9
132	Timing of Lung Transplantation for Patients with Fibrotic Lung Diseases. Seminars in Respiratory and Critical Care Medicine, 2001, 22, 517-532.	2.1	8
133	Schistosoma japonicum Soluble Egg Antigens Attenuate Invasion in a First Trimester Human Placental Trophoblast Model. PLoS Neglected Tropical Diseases, 2013, 7, e2253.	3.0	8
134	Adipose Stromal Cell-Secretome Counteracts Profibrotic Signals From IPF Lung Matrices. Frontiers in Pharmacology, 2021, 12, 669037.	3.5	8
135	Accessory Cardiac Bronchus. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 825-825.	5.6	6
136	Routine Chest Radiography for the Evaluation of Pneumothorax Following Bronchoscopy. Academic Radiology, 2019, 26, 585-590.	2.5	5
137	Innate Pathways Shape Sarcoidosis Signaling. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 425-427.	5.6	4
138	Mucking around in the Genome: MUC5B in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 355-357.	5.6	4
139	Plakoglobin expression in fibroblasts and its role in idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2015, 15, 140.	2.0	3
140	Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial. , 2019, , .		3
141	Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil., 2019,,.		3
142	Effect of nintedanib on blood biomarkers in patients with IPF in the INMARK trial., 2019,,.		3
143	Bronchoscopic Evaluation of Pulmonary Complications in Patients Undergoing Reduced-Intensity Versus Full-Intensity Transplants Blood, 2008, 112, 2163-2163.	1.4	3
144	Comparative Biology of the Normal LungÂExtracellular Matrix., 2015,, 387-402.		2

#	Article	lF	Citations
145	Management of Wegener Granulomatosis. Clinical Pulmonary Medicine, 2005, 12, 220-231.	0.3	1
146	The Fibrosis Across Organs Symposium: A Roadmap for Future Research Priorities. American Journal of the Medical Sciences, 2019, 357, 405-410.	1.1	1
147	Microbes mediated host innate immune response in idiopathic pulmonary fibrosis. , 2016, , .		1
148	Corticosteroid Therapy for Sarcoidosis. Lung Biology in Health and Disease, 2005, , 689-716.	0.1	1
149	Effects of nintedanib on markers of epithelial damage in subjects with IPF: data from the INMARK trial. , 2020, , .		1
150	Reliability, construct validity and responsiveness to change of the PROMIS-29 in systemic sclerosis-associated interstitial lung disease. Clinical and Experimental Rheumatology, 2019, 37 Suppl 119, 49-56.	0.8	1
151	Pulmonary Vasculitis., 2007, 36, 196-211.		0
152	Commentary: A Breath of Fresh Air on the Mesenchyme: Impact of Impaired Mesenchymal Development on the Pathogenesis of Bronchopulmonary Dysplasia. Frontiers in Medicine, 2016, 3, 13.	2.6	0
153	TGF- $\hat{I}^2$ Induced Collagen Remodelling by IPF Fibroblasts is Alleviated by Inhibition of Lysyl Oxidase Enzyme Activity. QJM - Monthly Journal of the Association of Physicians, 2016, , .	0.5	0
154	Adoption of Antifibrotic Medications: A Closer Look at the Data. Annals of the American Thoracic Society, 2021, 18, 1756-1757.	3.2	0
155	Conformational coupling of integrin and Thy-1 regulates Fyn priming and fibroblast mechanotransduction. Journal of General Physiology, 2015, 146, 1465OIA57.	1.9	0
156	Investigating effects of nintedanib on biomarkers of ECM turnover in patients with IPF: the INMARK study. , $2018,  \ldots$		0
157	Interstitial pneumonia with autoimmune features (IPAF): a clinical entity?., 2019,,.		0
158	Impact of comorbidities in interstitial pneumonia with autoimmune features (IPAF). , 2019, , .		0
159	Interpretation of PFTs and Decline in PFTs. In Clinical Practice, 2021, , 139-149.	0.0	0
160	Changes in biomarkers with nintedanib and sildenafil in subjects with IPF in the INSTAGE trial: subgroup analysis by right heart dysfunction (RHD)., 2020,,.		0
161	Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial. , 2020, , .		0